2025-11-21T10:59:52-06:00 2025-06-30 560587953 GILLIAM BELL MOSER LLP POST OFFICE BOX 621 BURLINGTON NC 272160621 990 2024-07-01 383102731 PAVILLON INTERNATIONAL PAVI 8286258210 241 PAVILLON PLACE MILL SPRING NC 28756 BARBARA BENNETT CHIEF EXECUTIVE OFFICER 8286258210 2025-11-20 1 0 BRETT D DAVIDSON P01279669 3362276283 2025-11-19 2024 2025-03-06 01:10:19Z BARBARA BENNETT 241 PAVILLON PLACE MILL SPRING NC 28756 11751202 0 X WWW.PAVILLON.ORG X 1993 MI TO BRING HOPE, HEALING, AND LASTING RECOVERY TO INDIVIDUALS AND FAMILIES WHO SUFFER FROM ALCOHOLISM, DRUG ADDICTIONS AND RELATED DISORDERS. 12 12 128 0 0 0 156943 297750 12054130 11239405 88785 87854 81545 74276 12381403 11699285 932101 554223 0 0 8577931 8569220 0 0 20923 4083987 3741468 13594019 12864911 -1212616 -1165626 9606855 8544414 1587590 1690775 8019265 6853639 X TO PROVIDE HOPE, HEALING, AND LASTING RECOVERY TO INDIVIDUALS AND THEIR FAMILIES WHO SUFFER FROM ALCOHOLISM AND OTHER SUBSTANCE USE RELATED DISORDERS. 0 0 9676525 524212 10701045 PRIMARY RESIDENTIAL PROGRAM: PAVILLON'S PROGRAM PHILOSOPHY IS ONE OF ENSURING CESSATION OF ILLICIT USE OF SUBSTANCES WITH ADDICTION POTENTIAL (RATHER THAN REDUCED OR MODERATED USE), AND IS ROOTED IN THE EVIDENCE-BASED CLINICAL PRACTICE OF 12 STEP FACILITATION. WE PRESCRIBE MEDICATIONS ON AN INDIVIDUALIZED BASIS AS DETERMINED BY OUR MEDICAL STAFF FOR SUBSTANCE USE DISORDERS AS WELL AS PSYCHIATRIC CONDITIONS. CLINICAL PROGRAMMING INCLUDES ADDITIONAL EVIDENCE-BASED PRACTICES, SUCH AS: GENDER-SPECIFIC CARE, COGNITIVE-BEHAVIORAL THERAPY, MOTIVATIONAL INTERVIEWING, PERSON-CENTERED COUNSELING, EXPERIENTIAL THERAPIES, TRAUMA-INFORMED THERAPIES (E.G. EMDR), AND OPTIONS SUCH AS ACUPUNCTURE AND MASSAGE. IMPROVEMENTS EXPERIENCED IN THE PRIMARY PROGRAM PROGRESSES THROUGH THE FOLLOWING THREE (3) STAGES. IN TERMS OF NEUROBIOLOGY AND PHYSIOLOGY, IT IS COMMON FOR SOMEONE TO EXPERIENCE COGNITIVE CLEARING. AFTER THEIR SUBSTANCE USE OR DRINKING HAS STOPPED AND WHILE THEIR COGNITION IS CLEARING, THEIR PHYSIOLOGY IS ALSO CONTINUING TO ADAPT TO THE ABSENCE OF SUBSTANCES. DURING THIS STAGE THE PERSON IS GAINING AN ABILITY TO LEARN FROM THE TREATMENT PROGRAM, AS THEY PARTICIPATE, DEPENDING ON THE PERSON'S USE PATTERN AND THE SPECIFIC SUBSTANCES THEY WERE TAKING PRIOR TO ADMISSION. INITIAL FEELINGS OF DENIAL, ANGER, BLAMING, GRIEF AND SADNESS CAN BE PRESENT. DURING THE SECOND STAGE OF PERSONS STAY, THEY BEGINS TO DEVELOP IMPORTANT INSIGHTS. THEY BEGIN TO SEE THAT THERE IS ANOTHER WAY FOR THEM TO LIVE. THE PERSON WORKS ON THEIR RECOVERY NEEDS WITH OTHER PEOPLE AND BEGINS TO REALIZE THERE ARE OTHER PEOPLE JUST LIKE THEM. THIS RAISES HOPE. THE PERSON ALSO BEGINS TO SEE WHAT HAS HAPPENED AS A RESULT OF THEIR SUBSTANCE USE. THEY BEGIN TO REALIZE WHAT THEY HAVE DONE AND WHAT IT HAS CAUSED. THEY BEGIN TO PROCESS THIS WITH OTHERS, AND DOING SO IS A POWERFULLY POSITIVE EXPERIENCE. IN THE FINAL STAGE OF OUR PROGRAM, IMPORTANT CHANGES CONTINUE TO TAKE PLACE. IN TERMS OF NEUROBIOLOGY AND PHYSIOLOGY, THE PERSON IS STABLE AND CONTINUING TO IMPROVE. THEY BEGIN TO GAIN INSIGHT INTO WHAT TOOLS THEY WILL NEED TO IMPLEMENT FOR LASTING RECOVERY FOLLOWING THEIR TREATMENT. THEY BEGIN TO IDENTIFY THE PRACTICAL WAYS THEY WILL NEED TO IMPLEMENT THOSE TOOLS FOR RECOVERY. THEY GAIN SIGNIFICANT INSIGHTS ABOUT SOLUTIONS THAT MIGHT BE OUTSIDE OF THEMSELVES, AND BEGIN TO INTEGRATE HOW THOSE OUTSIDE SOLUTIONS CAN HELP AND ACTUALLY WORK TO SUPPORT RECOVERY. IN THE FINAL STAGE THEY ALSO PLAN FOR THE FEELINGS AND CIRCUMSTANCES RELATED TO RETURNING TO THEIR RELATIONSHIPS, HOME, WORK, SCHOOL, AND LIFE WITH OTHERS, INCLUDING THEIR FAMILY MEMBERS AND OTHER IMPORTANT SUPPORTIVE PEOPLE. THIS PROCESS OF RECOVERY PLANNING AND CONTINUING CARE PLANNING IS VITAL. FOR FISCAL YEAR ENDING IN 2025, PAVILLON RECEIVED 1,325 INQUIRIES REGARDING OUR TREATMENT PROGRAM, RESULTING IN 390 ADMISSIONS, 14,026 PATIENT DAYS, AND AN AVERAGE LENGTH OF STAY OF 36 DAYS. WE COMPLETED 54 PROFESSIONAL 4-DAY EVALUATIONS. 2148 116 2376 EXTENDED CARE PROGRAM: PATIENTS MAY INDIVIDUALIZE THEIR LENGTH OF STAY AFTER PRIMARY TREATMENT, AND CONTINUE IN OUR EXTENDED CARE PROGRAM IF AND AS NEEDED. INDICATORS FOR ADDING THE EXTENDED CARE PHASE OF TREATMENT INCLUDE MATTERS OF CLINICAL COMPLEXITY SUCH AS PSYCHIATRIC CONDITIONS, PREVIOUS TREATMENT EPISODES FOR SUBSTANCE USE DISORDERS, PREVIOUS TIME IN RECOVERY FROM SUBSTANCE USE DISORDERS, ADVERSE FACTORS DURING THEIR UPBRINGING IN THEIR FAMILY OF ORIGIN, CURRENT FAMILY SYSTEM DYNAMICS, AND PERSONALITY FACTORS THAT MIGHT SERVE AS BARRIERS TO PERSONAL RECOVERY. THAT PROGRAM SPECIALIZES IN RELAPSE PREVENTION THERAPY WITH A FOCUS ON NAVIGATING UNDERLYING CORE ISSUES IN THE CONTEXT OF THEIR CURRENT LIFE EXPERIENCE THAT CAN CONTRIBUTE TO THE RELAPSE PROCESS. DURING FISCAL YEAR ENDING IN 2025, OUR EXTENDED CARE PROGRAM TREATED 107 PATIENTS RESULTING IN 2,317 PATIENT DAYS AND AN AVERAGE LENGTH OF STAY OF 22 DAYS. 551834 29895 610260 INTENSIVE OUTPATIENT PROGRAM (IOP): OUR ORGANIZATION PROVIDES A VIRTUAL INTENSIVE OUTPATIENT PROGRAM (IOP) FOR SUBSTANCE USE DISORDERS AND THIS CAN INCLUDE PEOPLE WITH A CO-OCCURRING PSYCHIATRIC CONDITIONS. THE IOP CAN SERVE AS THE PRIMARY TREATMENT FOR THOSE NEEDING TO BEGIN CARE OR AS A STEP-DOWN NEXT LEVEL OF CARE FROM A RESIDENTIAL PROGRAM INCLUDING PROGRAMS OTHER THAN PROVIDED BY PAVILLON. THE IOP IS OFFERED IN 3 GROUPS PER WEEK IN A DAYTIME TRACK OR AN EVENING TRACK. FOLLOWING IOP WE OFFER A STEP-DOWN LEVEL OF CARE TWICE PER WEEK IN THE SAME TRACKS. WE ALSO OFFER A ONCE-PER-WEEK STEP DOWN LEVEL OF CARE FOLLOWING THE TWICE-PER-WEEK LEVEL. PAVILLON PROVIDES A 12 MONTH LONG WEEKLY GROUP THERAPY ON AN OUTPATIENT BASIS THAT SPECIFICALLY FOCUSES ON THOSE PEOPLE WITH CHRONIC RELAPSE HISTORIES AND NEEDING TO ADDRESS THE UNDERLYING DYNAMICS LEADING TO RETURN TO USE. INDIVIDUAL SESSIONS AND PSYCHIATRIC MEDICATION MANAGEMENT CAN BE PROVIDED FOR PEOPLE RECEIVING OUR OUTPATIENT CARE, IF AND AS NEEDED. FURTHER, WE PROVIDE AN OUTPATIENT ONE DAY ASSESSMENT DETERMINING THE PRESENCE OR ABSENCE OF A SUBSTANCE USE DISORDER, IF SUCH AN EXTENDED EVALUATION METHOD IS NEEDED. FOR FISCAL YEAR ENDING IN 2025, WE COMPLETED A TOTAL OF 1,659 IOP SESSIONS, 323 GROUP THERAPY SESSIONS, 832 RELAPSE PREVENTION SESSIONS, 864 INDIVIDUAL AND MEDICATION MANAGEMENT OFFICE VISITS. 10230507 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 71 0 128 1 0 0 0 0 0 0 0 0 0 0 X 12 12 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 X X JOHN PEARSON 8286942300 241 PAVILLON PLACE MILL SPRINGS NC 28756 BARBARA BENNETT CEO 40.00 X X 270828 0 9320 MARK BUTHMAN BOARD CHAIR 2.00 X 0 0 0 CONNIE C MELE BOARD VICE CHAIR 2.00 X 0 0 0 LANIER CANSLER BOARD TREASURER 2.00 X 0 0 0 CHERYL KAYNARD JD MPA BOARD MEMBER 1.00 X 0 0 0 PRESTON MILLER BOARD MEMBER 1.00 X 0 0 0 VERLA NESLUND BOARD SECRETARY 2.00 X 0 0 0 KEITH WOOD BOARD MEMBER 1.00 X 0 0 0 DAVID TRUSCOTT BOARD MEMBER 1.00 X 0 0 0 MELISSA WITMEIER BOARD MEMBER 1.00 X 0 0 0 JULIE HUNEYCUTT BOARD MEMBER 1.00 X 0 0 0 JOHN MANN BOARD MEMBER 1.00 X 0 0 0 BRIAN COON CHEIF MEDICAL OFFICER 40.00 X 145102 0 6280 MICHAEL WILKERSON MD MEDICAL DIRECTOR 40.00 X 492288 0 37245 SHAY ALLEN DIRECTOR OF BUSINESS DEVEL 40.00 X 204959 0 7485 JOHN PEARSON DIRECTOR OF FINANCE 40.00 X 106997 0 11897 DENISE KAGAN LEAD PSYCHOLOGIST 40.00 X 131063 0 23260 HUNTER RAGLAND MARKETING REPRESENTATIVE 40.00 X 119847 0 9043 JUDITH WHITMAN PHYSICIAN ASSISTANT 40.00 X 122779 0 5452 KENT SPEAR CFO THRU MARCH 2024 40.00 X 153039 0 5192 1746902 0 115174 9 1 1 0 0 297750 39462 297750 PATIENT FEES 623990 11239405 11239405 11239405 90886 90886 3032 -3032 -3032 -3032 87598 48885 38713 38713 MISCELLANEOUS INCOME 900099 35563 35563 35563 11699285 11313681 0 87854 554223 554223 1021288 950701 70568 19 6145599 4827218 1317255 1126 153069 126376 26660 33 750074 619269 130642 163 499190 406118 92989 83 7500 7500 53648 53648 522554 288659 233895 81814 740 81074 133249 103043 29059 1147 369884 344704 24388 792 86605 9789 76814 2 51427 24833 26583 11 658649 599172 59477 180194 13494 166700 SUPPLIES 642778 625867 16865 46 PURCHASED SERVICES 523988 463137 60278 573 LICENSES & TAXES 232892 185732 30236 16924 OTHER EXPENSE 102544 1696 100844 4 93742 85736 8006 12864911 10230507 2613481 20923 1026102 980448 2191635 1778205 782027 854317 17347 18267 75063 52817 16738559 12020164 5316836 4718395 177924 123820 19921 18145 9606855 8544414 1024799 1361539 436078 248836 126713 80400 1587590 1690775 X 7810416 6644790 208849 208849 8019265 6853639 9606855 8544414 -1165626 0 X 0 1 X 1 0 X 1417104 2748227 208554 156943 297750 4828578 9781422 9287773 10490684 12143836 11327004 53030719 11198526 12036000 10699238 12300779 11624754 57859297 12310 5960 15260 9125 25700 68355 0 12310 5960 15260 9125 25700 68355 57790942 1389 2606 308748 135065 90886 538694 1389 2606 308748 135065 90886 538694 25341 26206 60268 41740 35563 189118 11225256 12064812 11068254 12477584 11751203 58587109 0.98640 0.98700 0.00920 0.00890 X SCHEDULE A, PART III, LINE 12, EXPLANATION OF OTHER INCOME: MISCELLANEOUS INCOME - 2020 AMOUNT: $ 25,341. 2021 AMOUNT: $ 26,206. 2022 AMOUNT: $ 53,508. 2023 AMOUNT: $ 41,740. 2024 AMOUNT: $ 35,563. WORKSHOPS - 2022 AMOUNT: $ 6,760. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 793849 793849 12994375 9562467 3431908 1737786 1350372 387414 1212549 1107325 105224 4718395 OPERATING LEASE LIABILITIES 80400 80400 11145062 0 11145062 554223 554223 11699285 12310688 0 12310688 554223 554223 12864911 PART XI, LINE 4B - OTHER ADJUSTMENTS: SCHOLARSHIPS NETTED AGAINST PATIENT FEES ON FINANCIAL STATEMENTS 554,223. PART XII, LINE 4B - OTHER ADJUSTMENTS: SCHOLARSHIPS NETTED AGAINST PATIENT FEES ON FINANCIAL STATEMENTS 554,223. 1 FINANCIAL AID 101 554223 FMV REDUCTION IN TOTAL FEES FUNDED FROM SCHOLARSHIP FUND. PART I, LINE 2: DOLLARS THAT HAVE BEEN DESIGNATED AS GRANT/SCHOLARSHIP MONEY ARE RECORDED INTO A SEPARATE GENERAL LEDGER ACCOUNT FOR VISIBILITY. ANY MONEY AWARDED TO PATIENTS REQUESTING FINANCIAL ASSISTANCE MUST BE APPROVED BY OUR EXECUTIVE STAFF (CEO OR CFO). ONCE APPROVED, THE GRANT IS CREDITED TO THE PATIENT'S ACCOUNT AND THE GRANT FUND IS REDUCED BY THE SAME AMOUNT. THE GRANT FUND IS THEN RECONCILED AT THE END OF EACH MONTH FOR ACCURACY. X X X 0 0 0 0 0 0 0 0 0 MICHAEL WILKERSON MD MEDICAL DIRECTOR 492288 0 0 0 0 0 13655 0 23590 0 529533 0 0 0 BARBARA BENNETT CEO 270828 0 0 0 0 0 0 0 9320 0 280148 0 0 0 SHAY ALLEN DIRECTOR OF BUSINESS DEVEL 204959 0 0 0 0 0 7485 0 0 0 212444 0 0 0 KENT SPEAR CFO THRU MARCH 2024 53485 0 0 0 99554 0 2609 0 2583 0 158231 0 0 0 DENISE KAGAN LEAD PSYCHOLOGIST 131063 0 0 0 0 0 5672 0 17588 0 154323 0 0 0 BRIAN COON CHEIF MEDICAL OFFICER 145102 0 0 0 0 0 5885 0 395 0 151382 0 0 0 X 300 39462 FMV 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE COMPLETED FORM 990 WILL BE PRESENTED TO THE BOARD OF DIRECTORS FOR THEIR REVIEW BEFORE IT IS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C MONITORING AND ENFORCEMENT OF OUR CONFLICT OF INTEREST POLICY ARE ACCOMPLISHED IN THE FOLLOWING MANNER: 1) ANNUALLY ALL DIRECTORS, TRUSTEES, AND KEY EMPLOYEES ARE REQUIRED TO SIGN A DISCLOSURE LISTING ALL POTENTIAL CONFLICT OF INTEREST MATTERS. 2) AT THE BEGINNING OF EVERY BOARD MEETING, EACH BOARD MEMBER IS REQUESTED TO DISCLOSE ANY NEW OR ARISING CONFLICT OF INTEREST ISSUES SINCE THE LAST BOARD MEETING. 3) A CORPORATE COMPLIANCE PROGRAM HAS BEEN ESTABLISHED WHICH INCLUDES ONGOING EMPLOYEE TRAINING REGARDING COMPLIANCE ISSUES, REPORTING AND INVESTIGATION, AND CONFLICT OF INTEREST DISCLOSURES. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION OF THE CEO IS DETERMINED BY THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS USING VARIOUS FORMS OF COMPARABILITY DATA. COMPENSATION OF KEY EMPLOYEES WITHIN THE ORGANIZATION IS DETERMINED BY THE CEO AND SHARED WITH THE BOARD OF DIRECTORS. THE PROCESS CONSISTS OF REVIEWING THE SALARY AND BENEFITS PROVIDED AT SIMILAR TREATMENT CENTERS, COUPLED WITH THEIR EXPERIENCE AND CREDENTIALS. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS AND THE CONFLICT OF INTEREST POLICY ARE AVAILABLE ON THE INTRANET FOR ALL EMPLOYEES. THE FORM 990 IS AVAILABLE TO THE PUBLIC, AS REQUESTED.